EHVA initiates a clinical trial to test a combination of therapeutic vaccines and immunotherapy drug

The European HIV Vaccine Alliance (EHVA) announces the start of the EHVA T01 / ANRS VRI05 trial, with the initiation of screening of participants at the Lausanne University Hospital Switzerland. EHVA-T01 / ANRS VRI05, a phase I/II placebo-controlled randomised trial, will evaluate a combination of experimental therapeutic HIV vaccines and an experimental immunotherapy drug in people living with HIV across six countries in Europe – France, Germany, Italy Spain, Switzerland, and UK. Prof Yves Lévy is the coordinating investigator of EHVA-T01/ ANRS VRI05, which is sponsored by Inserm-ANRS and managed by The Medical Research Council Clinical Trials Unit at University College London.

Prof Yves Lévy, director of the VRI, is the coordinator of the EHVA consortium, a five year project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine (www.ehv-a.eu). The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine.